Pre-op topical analgesics vary in post-PRK pain control

Article

The duration and pattern of action of pain-suppressing nonsteroidal anti-inflammatory drugs (NSAIDs) used prior to photorefractive keratotomy (PRK) varies with the NSAID used, according to South Korean researchers.

The duration and pattern of action of pain-suppressing nonsteroidal anti-inflammatory drugs (NSAIDs) used prior to photorefractive keratotomy (PRK) varies with the NSAID used, according to South Korean researchers.

As reported in the Journal of Cataract and Refractive Surgery, the researchers conducted a comparative case series of 94 patients. The patients were randomly assigned to one of two groups. One group received ketorolac 0.5% in 1 eye and ofloxacin 0.3% in the other eye, the other group received diclofenac 0.1% in 1 eye and ofloxacin 0.3% in the other eye.

Three drops of each of the ophthalmic drugs were applied to each eye 30 minutes prior to PRK. The patients used a visual analogue scale to score the pain in each of their eyes at 6, 18, 24, 36, 48, 72 and 96 hours postoperatively.

The researchers found that the pain peaked between 24 and 36 hours postoperatively. The initial degree of pain reduction was constant for the NSAIDs, then dropped in the ketorolac group after 24 hours and in the diclofenac group after 36 hours. The postoperative time-serial pattern of the pain score changed in the diclofenac group compared with the pattern in the ofloxacin-treated eye; this change was not seen in the patients who received ketorolac. Neither NSAID affected visual outcomes.

To read an abstract of the study, visit the journal's website here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.